Executive Summary
Fresenius Medical Care Deutschland appealed a decision by the Controller General of Patents refusing to grant its patent application concerning microvesicles derived from adult stem cells for tumor treatment. The core legal dispute centered on whether the appellant could amend the claims at the appellate stage to overcome objections regarding novelty and inventive step. The Delhi High Court ultimately allowed the amendments, finding that they were merely explanatory or disclaimers and did not broaden the scope of the original claims. Consequently, the refusal order was set aside, and the matter was remanded back to the Patent Office for fresh examination.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Fresenius Medical Care Deutschland GmbH vs Controller General Of Patents, Designs And Trademarks and Anr is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Wieden+Kennedy India Private LimitedvsJindal Steel And Power Limited
Wieden+Kennedy India Private Limited approached the Delhi High Court seeking interim protection against Jindal Steel And Power Limited regarding an ad film campaign titled 'Steel of India'. The petitioner claimed authorship and copyright over the creative works, arguing that the respondent terminated the contract without fulfilling payment obligations. The court addressed the dispute under Section 9 of the Arbitration & Conciliation Act, 1996, while acknowledging the IP nature of the claim. The judgment mandated a deposit of Rs. 59 lakhs by the respondent and granted an interim injunction against distribution if the deposit was not made within two weeks.
J. Nageswara RaovsThe State Of Madras
The petitioner challenged the classification of his patented medicine, 'Vitogen', as 'medicated wine' and the associated duties levied under the Madras Prohibition Act. The court examined the scope of the Act and various notifications regarding medicinal preparations. While upholding the liability of 'Vitogen' to pay a specific duty (Rs. 35 per proof gallon) under Notification No. 473, the court declared certain provisions of the Act, including Section 23(2) and Notification No. 941, as ultra vires and unenforceable.
Paragon Cable India & Anr.vsEssee Networks Private Limited & Ors.
The Delhi High Court decreed the suit filed by Paragon Cable India against Essee Networks Private Limited, upholding a settlement agreement reached between the parties. The core dispute involved the infringement and passing off related to the trademark 'ELEKTRON'. Crucially, the court directed the Trademark Registry to expeditiously transfer the rights of the 'ELEKTRON' mark into the name of the plaintiffs, formalizing the assignment made by the defendants.
Master Drashtant Jhala Through His Next Friend and Natural Father Sh. Jaydeep Singh JhalavsUnion of India & Anr.
The petition addresses the extremely cumbersome and long-drawn process for procuring rare disease medicines on a patient-by-patient basis. The court directed M/s. Sarepta Therapeutics to place on record a general bulk procurement process and provide details of all its granted patents and patent applications in India related to DMD patients.
M/s. Dr.J.R.K's Research and Pharmaceuticals Private LimitedvsThe Registrar of Trademarks
The Madras High Court ruled in favor of M/s. Dr.J.R.K's Research and Pharmaceuticals Private Limited, directing the Registrar of Trademarks to accept and process a renewal application for the mark 'NATURE'S WEALTH RESTORES HEALTH.' The court held that as long as the trade mark has not been formally removed from the register, the proprietor is entitled to seek renewal, setting aside the rejection order issued by the Registry. This decision provides crucial protection against administrative hurdles preventing legitimate trademark renewals.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.